On Oct. 6, 2022, Merck announced data from two real-world evidence studies evaluating LAGEVRIOﾙ (molnupiravir), an investigational oral antiviral COVID-19 medicine.

In the Clalit observational, retrospective cohort study conducted in Israel , LAGEVRIO was associated with a lower rate of hospitalizations and mortality due to COVID-19 in patients 65 years and above, but not in younger adults.